- Home
- CNR vs PTGX Comparison
CNR vs PTGX Comparison
Compare CNR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNR
- PTGX
- Stock Information
- Founded
- CNR 1864
- PTGX 2006
- Country
- CNR United States
- PTGX United States
- Employees
- CNR N/A
- PTGX N/A
- Industry
- CNR Coal Mining
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- CNR Energy
- PTGX Health Care
- Exchange
- CNR Nasdaq
- PTGX Nasdaq
- Market Cap
- CNR 3.7B
- PTGX 3.3B
- IPO Year
- CNR N/A
- PTGX 2016
- Fundamental
- Price
- CNR $75.40
- PTGX $53.00
- Analyst Decision
- CNR Strong Buy
- PTGX Strong Buy
- Analyst Count
- CNR 4
- PTGX 9
- Target Price
- CNR $98.75
- PTGX $67.11
- AVG Volume (30 Days)
- CNR 1.0M
- PTGX 949.2K
- Earning Date
- CNR 08-15-2025
- PTGX 08-05-2025
- Dividend Yield
- CNR 0.55%
- PTGX N/A
- EPS Growth
- CNR N/A
- PTGX N/A
- EPS
- CNR 3.30
- PTGX 0.86
- Revenue
- CNR $2,663,948,000.00
- PTGX $207,801,000.00
- Revenue This Year
- CNR $91.77
- PTGX N/A
- Revenue Next Year
- CNR $9.51
- PTGX $53.09
- P/E Ratio
- CNR $22.89
- PTGX $61.45
- Revenue Growth
- CNR 11.29
- PTGX N/A
- 52 Week Low
- CNR $58.19
- PTGX $32.50
- 52 Week High
- CNR $134.59
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- CNR N/A
- PTGX 53.99
- Support Level
- CNR N/A
- PTGX $49.38
- Resistance Level
- CNR N/A
- PTGX $51.51
- Average True Range (ATR)
- CNR 0.00
- PTGX 2.02
- MACD
- CNR 0.00
- PTGX -0.39
- Stochastic Oscillator
- CNR 0.00
- PTGX 46.09
About CNR Core Natural Resources Inc. Common Stock
Core Natural Resources Inc is a producer and exporter of coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The principal activity involves mining, preparation, and marketing of thermal coal, sold to power generators.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.